A recent report from a non-profit, independant research group addresses the cost-effectiveness and budgetary impact of treatment with PCSK9 inhibitors.
An FDA advisory committee has voted to recommend approval of a new drug for the long-term treatment of patients with hypercholesterolemia and dyslipidemia.